Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

NCT03806127 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome

Interventions

DRUG: Vibegron
DRUG: Placebo

Sponsor

Urovant Sciences GmbH